Translating nucleic acid-sensing pathways into therapies (original) (raw)
Theofilopoulos, A. N., Baccala, R., Beutler, B. & Kono, D. H. Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol.23, 307–336 (2005). ArticleCASPubMed Google Scholar
Egli, A., Santer, D. M., O'Shea, D., Tyrrell, D. L. & Houghton, M. The impact of the interferon-λ family on the innate and adaptive immune response to viral infections. Emerg. Microbes Infect.3, e51 (2014). ArticleCASPubMedPubMed Central Google Scholar
Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol.32, 513–545 (2014). ArticleCASPubMedPubMed Central Google Scholar
Pichlmair, A. & Reis, E. Sousa, C. Innate recognition of viruses. Immunity27, 370–383 (2007). ArticleCASPubMed Google Scholar
García-Sastre, A. 2 methylate or not 2 methylate: viral evasion of the type I interferon response. Nat. Immunol.12, 114–115 (2011). ArticleCASPubMed Google Scholar
Morita, M. et al. Gene-targeted mice lacking the trex1 (DNase III) 3′→5′ DNA exonuclease develop inflammatory myocarditis. Mol. Cell. Biol.24, 6719–6727 (2004). ArticleCASPubMedPubMed Central Google Scholar
Yoshida, H., Okabe, Y., Kawane, K., Fukuyama, H. & Nagata, S. Lethal anemia caused by interferon-β produced in mouse embryos carrying undigested DNA. Nat. Immunol.6, 49–56 (2005). ArticleCASPubMed Google Scholar
Ahn, J., Ruiz, P. & Barber, G. N. Intrinsic self-DNA triggers inflammatory disease dependent on STING. J. Immunol.193, 4634–4642 (2014). ArticleCASPubMedPubMed Central Google Scholar
Lan, Y. Y., Londono, D., Bouley, R., Rooney, M. S. & Hacohen, N. Dnase2a deficiency uncovers lysosomal clearance of damaged nuclear DNA via autophagy. Cell Rep.9, 180–192 (2014). ArticleCASPubMedPubMed Central Google Scholar
Chan, M. P. et al. DNase II-dependent DNA digestion is required for DNA sensing by TLR9. Nat. Commun.6, 5853 (2015). ArticleCASPubMed Google Scholar
Pawaria, S. et al. Cutting edge: DNase II deficiency prevents activation of autoreactive B cells by double-stranded DNA endogenous ligands. J. Immunol.194, 1403–1407 (2015). ArticleCASPubMedPubMed Central Google Scholar
Woo, S.-R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity41, 830–842 (2014). This study was the first to indicate a crucial role for cytosolic sensing of self DNA in tumour surveillance. ArticleCASPubMedPubMed Central Google Scholar
Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature449, 564–569 (2007). This was the first paper to demonstrate that an antimicrobial peptide from psoriatic skin shuttles DNA into cells and induces type I IFN release via TLR9. ArticleCASPubMed Google Scholar
Lovgren, T., Eloranta, M. L., Bave, U., Alm, G. V. & Ronnblom, L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum.50, 1861–1872 (2004). This paper demonstrates that sera from patients with SLE can form immune complexes with necrotic material and induce type I IFN release from pDCs. ArticleCASPubMed Google Scholar
Bave, U. et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum.52, 1185–1195 (2005). ArticleCASPubMed Google Scholar
Tanji, H. et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat. Struct. Mol. Biol.22, 109–115 (2015). ArticleCASPubMed Google Scholar
Ohto, U. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature520, 702–705 (2015). References 18 and 19 provided the first structural insight into unexpected aspects of single-stranded nucleic acid ligand binding by TLR8 and TLR9, respectively. TLRs have proven notoriously difficult to express and crystallize. ArticleCASPubMed Google Scholar
Kato, H. et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med.205, 1601–1610 (2008). ArticleCASPubMedPubMed Central Google Scholar
Pichlmair, A. et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J. Virol.83, 10761–10769 (2009). ArticleCASPubMedPubMed Central Google Scholar
Hou, F. et al. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell146, 448–461 (2011). ArticleCASPubMedPubMed Central Google Scholar
Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science339, 786–791 (2013). ArticleCASPubMed Google Scholar
Wu, J. et al. Cyclic GMP–AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science339, 826–830 (2013). References 26 and 27 report the seminal discovery of the cytosolic DNA receptor, as well as the small-molecule second messenger, that links to STING activation. ArticleCASPubMed Google Scholar
Gao, P. et al. Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell153, 1094–1107 (2013). ArticleCASPubMedPubMed Central Google Scholar
Jin, L. et al. MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP. J. Immunol.187, 2595–2601 (2011). ArticleCASPubMedPubMed Central Google Scholar
Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science347, aaa2630 (2015). This study highlights a previously unappreciated role for adaptor phosphorylation as an integral step in the activation of nucleic acid signalling pathways. ArticleCASPubMed Google Scholar
Latz, E., Xiao, T. S. & Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol.13, 397–411 (2013). ArticleCASPubMed Google Scholar
Huen, A. O. & Rook, A. H. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr. Opin. Oncol.26, 237–244 (2014). ArticleCASPubMed Google Scholar
Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature470, 543–547 (2011). ArticleCASPubMedPubMed Central Google Scholar
Kastenmüller, K. et al. Protective T cell immunity in mice following protein–TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest.121, 1782–1796 (2011). ArticleCASPubMedPubMed Central Google Scholar
Ilyinskii, P. O. et al. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine32, 2882–2895 (2014). ArticleCASPubMedPubMed Central Google Scholar
Kastenmuller, W., Kastenmüller, K., Kurts, C. & Seder, R. A. Dendritic cell-targeted vaccines — hope or hype? Nat. Rev. Immunol.14, 705–711 (2014). ArticleCASPubMed Google Scholar
Field, A. K., Tytell, A. A., Lampson, G. P. & Hilleman, M. R. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc. Natl Acad. Sci. USA58, 1004–1010 (1967). ArticleCASPubMed Google Scholar
Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature413, 732–738 (2001). ArticleCASPubMed Google Scholar
Gitlin, L. et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA103, 8459–8464 (2006). ArticleCASPubMed Google Scholar
Caskey, M. et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med.208, 2357–2366 (2011). ArticleCASPubMedPubMed Central Google Scholar
Ammi, R. et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol. Ther.140, 120–131 (2014). Google Scholar
Strayer, D. R. et al. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS ONE7, e31334 (2012). ArticleCASPubMedPubMed Central Google Scholar
Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol.3, 196–200 (2002). ArticleCASPubMed Google Scholar
Baguley, B. C. & Ching, L. M. DMXAA: an antivascular agent with multiple host responses. Int. J. Radiat. Oncol. Biol. Phys.54, 1503–1511 (2002). ArticleCASPubMed Google Scholar
Lara, P. N. et al. Randomized Phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol.29, 2965–2971 (2011). ArticleCASPubMed Google Scholar
Conlon, J. et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J. Immunol.190, 5216–5225 (2013). ArticleCASPubMedPubMed Central Google Scholar
Gao, P. et al. Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA. Cell Rep.8, 1668–1676 (2014). ArticleCASPubMedPubMed Central Google Scholar
Karaolis, D. K. R. et al. Bacterial c-di-GMP is an immunostimulatory molecule. J. Immunol.178, 2171–2181 (2007). ArticleCASPubMed Google Scholar
Dubensky, T. W., Kanne, D. B. & Leong, M. L. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther. Adv. Vaccines1, 131–143 (2013). ArticleCASPubMedPubMed Central Google Scholar
Gao, P. et al. Structure–function analysis of STING activation by c[G(2′,5′)pA(3′,5′)p] and targeting by antiviral DMXAA. Cell154, 748–762 (2013). ArticleCASPubMedPubMed Central Google Scholar
Li, X.-D. et al. Pivotal roles of cGAS–cGAMP signaling in antiviral defense and immune adjuvant effects. Science341, 1390–1394 (2013). ArticleCASPubMed Google Scholar
Krieg, A. M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374, 546–549 (1995). ArticleCASPubMed Google Scholar
Scheiermann, J. & Klinman, D. M. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine32, 6377–6389 (2014). ArticleCASPubMedPubMed Central Google Scholar
Bedard, K. M. et al. Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J. Virol.86, 7334–7344 (2012). ArticleCASPubMedPubMed Central Google Scholar
Wang, Y. et al. Structural and functional insights into 5′-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat. Struct. Mol. Biol.17, 781–787 (2010). ArticleCASPubMedPubMed Central Google Scholar
Schlee, M. et al. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity31, 25–34 (2009). ArticleCASPubMedPubMed Central Google Scholar
Querec, T. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med.203, 413–424 (2006). ArticlePubMedPubMed Central Google Scholar
Goff, P. H. et al. Synthetic TLR4 and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained and broadly protective responses. J. Virol.89, 3221–3335 (2015). ArticleCASPubMedPubMed Central Google Scholar
Temizoz, B. et al. TLR9 and STING agonists synergistically induce innate and adaptive type II IFN. Eur. J. Immunol.45, 1159–1169 (2015). ArticleCASPubMedPubMed Central Google Scholar
Marshak-Rothstein, A. & Rifkin, I. R. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol.25, 419–441 (2007). A comprehensive review of the role of endosomal TLRs in SLE,with a particular focus on B cell biology. ArticleCASPubMed Google Scholar
Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med.202, 1131–1139 (2005). ArticleCASPubMedPubMed Central Google Scholar
Kuznik, A. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol.186, 4794–4804 (2011). ArticleCASPubMed Google Scholar
Sun, X. et al. Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J. Immunol.190, 2536–2543 (2013). ArticleCASPubMedPubMed Central Google Scholar
Kalunian, K. et al. Efficacy and safety of rontalizumab (anti-interferon α) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled Phase 2 study. Arthritis Rheumatol. Abstr. Suppl.64, S1111 (2012). A conference abstract showing that ISGs can be used for patient stratification in clinical studies. Google Scholar
Blomberg, S. et al. Presence of cutaneous interferon-α producing cells in patients with systemic lupus erythematosus. Lupus10, 484–490 (2001). ArticleCASPubMed Google Scholar
Farkas, L., Beiske, K., Lund-Johansen, F., Brandtzaeg, P. & Jahnsen, F. L. Plasmacytoid dendritic cells (natural interferon- α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol.159, 237–243 (2001). ArticleCASPubMedPubMed Central Google Scholar
Berghofer, B. et al. TLR7 ligands induce higher IFN-α production in females. J. Immunol.177, 2088–2096 (2006). ArticlePubMed Google Scholar
Laffont, S. et al. X-chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-α production of plasmacytoid dendritic cells from women. J. Immunol.193, 5444–5452 (2014). ArticleCASPubMed Google Scholar
Garcia-Romo, G. S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl Med.3, 73ra20 (2011). ArticlePubMedPubMed Central Google Scholar
Lande, R. et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl Med.3, 73ra19 (2011). ArticlePubMedPubMed Central Google Scholar
Leadbetter, E. A. et al. Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature416, 603–607 (2002). ArticleCASPubMed Google Scholar
Lau, C. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med.202, 1171–1177 (2005). ArticleCASPubMedPubMed Central Google Scholar
Chan, R. W. et al. Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proc. Natl Acad. Sci. USA111, E5302–E5311 (2014). ArticleCASPubMed Google Scholar
Vollmer, J. et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med.202, 1575–1585 (2005). ArticleCASPubMedPubMed Central Google Scholar
Annable, T. et al. Using poly I:C as an adjuvant does not induce or exacerbate models of systemic lupus erythematosus. Autoimmunity48, 29–39 (2015). ArticleCASPubMed Google Scholar
Deane, J. A. et al. Control of TLR7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity27, 801–810 (2007). ArticleCASPubMedPubMed Central Google Scholar
Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity25, 417–428 (2006). ArticleCASPubMed Google Scholar
Savarese, E. et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum.58, 1107–1115 (2008). ArticleCASPubMed Google Scholar
Wang, J. et al. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J. Biol. Chem.281, 37427–37434 (2006). ArticleCASPubMed Google Scholar
Fukui, R. et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity35, 69–81 (2011). ArticleCASPubMed Google Scholar
Nickerson, K. M. et al. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J. Immunol.184, 1840–1848 (2010). ArticleCASPubMedPubMed Central Google Scholar
Desnues, B. et al. TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc. Natl Acad. Sci. USA111, 1497–1502 (2014). ArticleCASPubMed Google Scholar
Fallarino, F. et al. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J. Immunol.183, 6303–6312 (2009). ArticleCASPubMed Google Scholar
Wingender, G. et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol.36, 12–20 (2006). ArticleCASPubMed Google Scholar
Moseman, E. A. et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol.173, 4433–4442 (2004). ArticleCASPubMed Google Scholar
Miles, K. et al. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc. Natl Acad. Sci. USA109, 887–892 (2012). ArticleCASPubMed Google Scholar
Pawar, R. D. et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol.18, 1721–1731 (2007). ArticleCASPubMed Google Scholar
Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C. & Coffman, R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol.37, 3582–3586 (2007). ArticleCASPubMed Google Scholar
Zhu, F. G. et al. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity46, 419–428 (2013). ArticleCASPubMed Google Scholar
van der Fits, L., van der Wel, L. I., Laman, J. D., Prens, E. P. & Verschuren, M. C. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-α sensitivity is unaltered. J. Investig. Dermatol.122, 51–60 (2004). ArticleCASPubMed Google Scholar
Ganguly, D. et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med.206, 1983–1994 (2009). ArticleCASPubMedPubMed Central Google Scholar
Yu, D. et al. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of Toll-like receptors 7 and 9. J. Med. Chem.52, 5108–5114 (2009). ArticleCASPubMed Google Scholar
Suarez-Farinas, M. et al. Treatment of psoriasis patients with IMO-3100 shows improvement in gene expression patterns of meta-analysis derived-3 transcriptome and IL-17 pathway. Arthritis Rheumatol. Abstr. Suppl.65, S495 (2013). Google Scholar
Langley, R. G. et al. Secukinumab in plaque psoriasis — results of two Phase 3 trials. N. Engl. J. Med.371, 326–338 (2014). ArticleCASPubMed Google Scholar
Suarez-Farinas, M. et al. Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS ONE8, e84634 (2013). ArticleCASPubMedPubMed Central Google Scholar
Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol.8, 942–949 (2007). ArticleCASPubMed Google Scholar
Balak, D. M. W. et al. Results from a randomized, double-blind, placebo-controlled, monotherapy trial of IMO-8400 demonstrate clinical proof-of-concept for Toll-like receptor 7. 8 and 9 antagonism in psoriasis (poster). 73rd Annual Meeting of the American Academy of Dermatology1805 (2015).
Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature470, 115–119 (2011). ArticleCASPubMed Google Scholar
Wang, J. Q., Jeelall, Y. S., Beutler, B., Horikawa, K. & Goodnow, C. C. Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance. J. Exp. Med.211, 413–426 (2014). ArticleCASPubMedPubMed Central Google Scholar
Crow, Y. J. Type I interferonopathies: Mendelian type I interferon up-regulation. Curr. Opin. Immunol.32, 7–12 (2015). ArticleCASPubMed Google Scholar
Lee-Kirsch, M. A. et al. Mutations in the gene encoding the 3′–5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet.39, 1065–1067 (2007). ArticleCASPubMed Google Scholar
Rice, G. I. et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat. Genet.46, 503–509 (2014). ArticleCASPubMedPubMed Central Google Scholar
Funabiki, M. et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity40, 199–212 (2014). ArticleCASPubMed Google Scholar
Crampton, S. P., Deane, J. A., Feigenbaum, L. & Bolland, S. Ifih1 gene dose effect reveals MDA5- mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity. J. Immunol.188, 1451–1459 (2012). ArticleCASPubMed Google Scholar
Sharma, S. et al. Suppression of systemic autoimmunity by the innate immune adaptor STING. Proc. Natl Acad, Sci. USA112, E710–E717 (2015). A provocative study showing that STING deficiency in mice unexpectedly exacerbates lupus-like disease. ArticleCAS Google Scholar
Huang, L. et al. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J. Immunol.191, 3509–3513 (2013). ArticleCASPubMedPubMed Central Google Scholar
Zhang, X. et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell51, 226–235 (2013). ArticleCASPubMed Google Scholar
Diner, E. J. et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep.3, 1355–1361 (2013). ArticleCASPubMedPubMed Central Google Scholar
Kranzusch, P. J., Lee, A. S.-Y., Berger, J. M. & Doudna, J. A. Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell Rep.3, 1362–1368 (2013). ArticleCASPubMedPubMed Central Google Scholar
Lamphier, M. et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol. Pharmacol.85, 429–440 (2014). ArticleCASPubMed Google Scholar
Baum, R. et al. Cutting edge: AIM2 and endosomal TLRs differentially regulate arthritis and autoantibody production in DNase II-deficient mice. J. Immunol.194, 873–877 (2015). ArticleCASPubMed Google Scholar
Gehrke, N. et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity39, 482–495 (2013). ArticleCASPubMed Google Scholar
Yu, P. et al. Nucleic acid-sensing toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity37, 867–879 (2012). ArticleCASPubMed Google Scholar
Ciancanelli, M. J. et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science348, 448–453 (2015). ArticleCASPubMedPubMed Central Google Scholar
Alsina, L. et al. A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4. Nat. Immunol.15, 1134–1142 (2014). ArticleCASPubMedPubMed Central Google Scholar
Kuemmerle-Deschner, J. B. et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res. Ther.13, R34 (2011). ArticleCASPubMedPubMed Central Google Scholar
Ruperto, N. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med.367, 2396–2406 (2012). ArticleCASPubMed Google Scholar
West, A. P. et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature520, 553–557 (2015). References 9, 123 and 127 uncover physiological circumstances in which mitochondrial DNA is released as a cell-intrinsic danger signal leading to cGAS-mediated immune activation. ArticleCASPubMedPubMed Central Google Scholar
Khamashta, M. et al. Safety and efficacy of sifalimumab, an anti IFN-α monoclonal antibody, in a Phase 2b study of moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheum.66, 3531 (2014). Google Scholar
Morehouse, C. et al. Target modulation of a type I interferon (IFN) gene signature with sifalimumab or anifrolumab in systemic lupus erythematosis (SLE) patients in two open label Phase 2 Japanese trials. Arthritis Rheumatol. Abstr. Suppl.66, S313–S314 (2014). Google Scholar
Lauwerys, B. R. et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum.65, 447–456 (2013). ArticleCASPubMed Google Scholar
Zimmer, R., Scherbarth, H. R., Rillo, O. L., Gomez-Reino, J. J. & Muller, S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled Phase IIb clinical trial. Ann. Rheum. Dis.72, 1830–1835 (2013). ArticleCASPubMed Google Scholar
Reilly, S. M. et al. An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. Nat. Med.19, 313–321 (2013). ArticleCASPubMedPubMed Central Google Scholar
Chaudhary, D., Robinson, S. & Romero, D. L. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J. Med. Chem.58, 96–110 (2015). ArticleCASPubMed Google Scholar
Balasubramanian, W. R. et al. Novel IRAK-4 inhibitors exhibit highly potent anti-proliferative activity in DLBCL cell lines with activating MYD88 L265P mutation. AACR Annual Meeting Abstract3646 (2015).
Vajda, E. G., Niecestro, R., Zhi, L. & Marschke, K. B. IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B cell lymphomas. AACR Annual Meeting Abstract785 (2015).
Laska, M. J. et al. Polymorphisms within Toll-like receptors are associated with systemic lupus erythematosus in a cohort of Danish females. Rheumatol.53, 48–55 (2014). ArticleCAS Google Scholar
Assmann, T. S., Brondani Lde, A., Bauer, A. C., Canani, L. H. & Crispim, D. Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus. Eur. J. Endocrinol.170, 519–527 (2014). ArticleCASPubMed Google Scholar
Garcia-Ortiz, H. et al. Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann. Rheum. Dis.69, 1861–1865 (2010). ArticleCASPubMed Google Scholar
Kawasaki, A. et al. TLR7 single-nucleotide polymorphisms in the 3′ untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis Res. Ther.13, R41 (2011). ArticleCASPubMedPubMed Central Google Scholar
Piotrowski, P., Lianeri, M., Wudarski, M., Olesinska, M. & Jagodzinski, P. P. Contribution of toll-like receptor 9 gene single-nucleotide polymorphism to systemic lupus erythematosus. Rheumatol. Int.33, 1121–1125 (2013). ArticleCASPubMed Google Scholar
Cen, H. et al. Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Autoimmunity46, 455–462 (2013). ArticleCASPubMed Google Scholar
Tansley, S. L. et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res. Ther.16, R138 (2014). ArticleCASPubMedPubMed Central Google Scholar
Nejentsev, S., Walker, N., Riches, D., Egholm, M. & Todd, J. A. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science324, 387–389 (2009). ArticleCASPubMedPubMed Central Google Scholar
Shigemoto, T. et al. Identification of loss of function mutations in human genes encoding RIG-I and mda5: implications for resistance to type I diabetes. J. Biol. Chem.284, 13348–13354 (2009). ArticleCASPubMedPubMed Central Google Scholar
Crow, Y. J. et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. _Am. J. Med. Genet. A_167A, 296–312 (2015). A comprehensive review on AGS and its underlying genetic causes.
Ravenscroft, J. C., Suri, M., Rice, G. I., Szynkiewicz, M. & Crow, Y. J. Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus. Am. J. Med. Genet. A155A, 235–237 (2011). ArticlePubMed Google Scholar
Richards, A. et al. C-terminal truncations in human 3′–5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat. Genet.39, 1068–1070 (2007). ArticleCASPubMed Google Scholar
Jang, M. A. et al. Mutations in DDX58, which encodes RIG-I, cause atypical Singleton–Merten syndrome. Am. J. Hum. Genet.96, 266–274 (2015). ArticleCASPubMedPubMed Central Google Scholar
Zhang, X. et al. Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation. Nature517, 89–93 (2015). ArticleCASPubMed Google Scholar
Belot, A. et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr. Rheumatol. Online J.12, 44 (2014). ArticlePubMedPubMed Central Google Scholar
Briggs, T. A. et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet.43, 127–131 (2011). ArticleCASPubMed Google Scholar
Schuberth-Wagner, C. et al. A conserved histidine in the RNA sensor RIG-I controls immune tolerance to N1-2′O-methylated self RNA. Immunity43, 41–51 (2015). ArticleCASPubMed Google Scholar
Mannion N. M. et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Reports9, 1482–1494 (2015). ArticleCAS Google Scholar